Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO

A phase 2 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 200 participants.

Also called NCT07499037

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 200 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07499037
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
Czechia (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07499037. Non-randomized; no masking; primary purpose treatment. Start 2027-01 (anticipated); primary completion 2029-09 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Safety and Efficacy of Low-dose Anticoagulation With Argatroban and Enoxaparin on ECMO
Condition
Pneumonia
Condition
Heart Failure
Intervention (Drug)
Low anticoagulation dose of argatroban and enoxaparin during ECMO
Intervention (Drug)
Standard anticoagulation dose of argatroban and enoxaparin during ECMO
Lead sponsor
University Hospital Ostrava (class: other)
Collaborator
University Hospital, Motol (class: other)

Record details

Record id
cardio:ct-nct07499037
Content hash
6ad17e8be3f7161ebc512721cc61920e2852a59c7bd55b513f011672668dc0b4